Delta-Fly Pharma, Inc. (4598) AI Stock Analysis

• Market Cap: ¥5.48B
• Dividend Yield: N/A
• Average Volume (3M): 379.72K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.85
• Revenue Growth: N/A
• EPS Growth: 25.25%
• Country: JP
• Employees: 13
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -41.61
• Shares Outstanding: 12,159,900
• 10 Day Avg. Volume: 693,770
• 30 Day Avg. Volume: 379,723
• PEG Ratio: 1.82
• Price to Book (P/B): 18.22
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.76
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: ¥492.00 ▼(-2.96% Downside)

The score is primarily weighed down by weak financial performance (no recent revenue, widening losses, and accelerating cash burn with an eroding equity base), which raises funding and dilution risk. Technicals are neutral-to-soft and do not meaningfully offset fundamentals, while valuation is constrained by a negative P/E and lack of dividend yield data.

Positive Factors

Low Leverage

Minimal debt reduces financial risk and provides some flexibility, which is crucial for navigating periods of financial instability.

Prior Revenue Achievement

The ability to generate revenue in the past suggests potential for recovery if strategic initiatives or partnerships are successfully executed.

Biotechnology Industry

Operating in the biotechnology sector offers significant growth potential due to ongoing demand for innovative healthcare solutions.

Negative Factors

Widening Losses

Continued widening losses indicate structural profitability challenges, raising concerns about long-term financial sustainability.

Accelerating Cash Burn

Accelerating cash burn increases funding risk and the likelihood of needing additional financing, which could lead to dilution.

Eroding Equity Base

A declining equity base reflects sustained losses and capital depletion, limiting financial flexibility and increasing dilution risk.

Delta-Fly Pharma, Inc. Business Overview & Revenue Model

Company Description

Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase III clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is in preclinical trial to treat gastric/ovarian cancer. Delta-Fly Pharma, Inc. was incorporated in 2010 and is headquartered in Tokushima, Japan.

How the Company Makes Money

Delta-Fly Pharma, Inc. generates revenue primarily through the development and commercialization of its pharmaceutical products. The company's revenue streams include out-licensing agreements, collaborative partnerships, and milestone payments from pharmaceutical companies that partner with Delta-Fly Pharma to further develop and market its drug candidates. Additionally, the company may earn income from royalties on product sales once its therapeutic candidates receive regulatory approval and are commercialized. Strategic alliances and research partnerships are significant factors contributing to Delta-Fly Pharma's earnings, enabling the company to leverage the resources and expertise of larger pharmaceutical firms to bring its innovations to market.

Delta-Fly Pharma, Inc. Financial Statement Overview

Summary

Delta-Fly Pharma, Inc. is facing significant financial challenges, characterized by a lack of revenue in recent periods and persistent operational losses. The strong equity position, due to no debt, offers some buffer, but the absence of cash flow from operations is concerning. The biotech industry often involves high risk and substantial investment before profitability, and this company appears to be in the early stages of this cycle, with potential liquidity risks.

Income Statement

Delta-Fly Pharma, Inc. shows no revenue in the TTM period, leading to a lack of profitability metrics such as gross profit margin and net profit margin. The company has experienced a significant decline in revenue from 2022, with consistent negative EBIT and EBITDA, indicating ongoing operational losses. Revenue growth is negative due to the absence of revenue, which poses a challenge for financial sustainability.

Balance Sheet

The balance sheet reflects a strong equity position with no debt, resulting in a debt-to-equity ratio of 0, which is typically favorable. However, the company’s significant losses have eroded stockholders' equity over time. The equity ratio remains high, indicating reliance on equity financing. While the lack of debt reduces financial risk, ongoing losses may threaten future stability.

Cash Flow

The company’s cash flow statement reveals an absence of free cash flow growth and operating cash flow. The lack of operating cash flow is concerning and suggests that the company is not generating cash from its core activities. Free cash flow remains negative, indicating potential liquidity challenges. The absence of cash flow from operations to support net income is a significant risk.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	300.00M	300.00M
Gross Profit	-1.55M	-1.59M	-1.51M	-1.63M	300.00M	300.00M
EBITDA	-1.57B	-1.72B	-1.40B	-1.32B	-960.00M	-857.32M
Net Income	-1.59B	-1.72B	-1.43B	-1.33B	-967.30M	-862.59M
Balance Sheet
Total Assets	790.57M	434.33M	1.47B	906.82M	1.32B	2.16B
Cash, Cash Equivalents and Short-Term Investments	730.32M	338.83M	1.42B	844.34M	1.27B	2.09B
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	137.03M	156.54M	241.50M	115.62M	91.19M	82.46M
Stockholders Equity	653.55M	277.80M	1.23B	791.20M	1.23B	2.08B
Cash Flow
Free Cash Flow	0.00	-1.83B	-1.28B	-1.30B	-940.40M	-727.15M
Operating Cash Flow	0.00	-1.83B	-1.28B	-1.30B	-940.40M	-726.65M
Investing Cash Flow	0.00	-206.00K	207.00K	-326.00K	0.00	-505.00K
Financing Cash Flow	0.00	756.70M	1.85B	882.62M	119.86M	875.31M

Delta-Fly Pharma, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 507.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4598, the sentiment is Negative. The current price of 507 is above the 20-day moving average (MA) of 501.75, below the 50-day MA of 511.88, and below the 200-day MA of 562.20, indicating a bearish trend. The MACD of -18.64 indicates Positive momentum. The RSI at 30.67 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4598.

Delta-Fly Pharma, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4588	50 Neutral	¥44.44B	-18.47	―	―	-9.04%	13.09%
4583	45 Neutral	¥8.01B	-8.70	―	―	25.28%	39.15%
4598	44 Neutral	¥5.48B	-2.78	―	―	―	25.25%
4884	42 Neutral	¥2.96B	-3.04	―	―	-9.77%	-13.86%
4564	42 Neutral	¥8.92B	-8.34	-63.25%	―	99.87%	40.60%
4594	39 Underperform	¥5.99B	-4.59	―	―	1221.43%	30.54%